FilingReader Intelligence
Shandong Lukang begins phase I trial for rheumatoid arthritis drug
August 20, 2025 at 05:01 AM UTC•By FilingReader AI
Shandong Lukang Pharmaceutical has enrolled the first patient in its phase I clinical trial for CIGB-814, a potential rheumatoid arthritis treatment.
The class 1 chemical drug is designed as an immune modulator that regulates immune responses by affecting CD4+T cells and reducing inflammatory cytokines including IL-17 and TNF-α.
The company received clinical trial approval from China's National Medical Products Administration in November 2024.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Shandong Lukang Pharmaceutical publishes news
Free account required • Unsubscribe anytime